Patents by Inventor C. Simone Jude-Fishburn
C. Simone Jude-Fishburn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210401998Abstract: The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.Type: ApplicationFiled: May 13, 2021Publication date: December 30, 2021Inventors: Michael A. Eldon, C. Simone Jude-Fishburn, Hema Gursahani, Myong Gyong Lee
-
Publication number: 20210393513Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.Type: ApplicationFiled: August 23, 2021Publication date: December 23, 2021Inventors: C. Simone Jude-Fishburn, David Lechuga-Ballesteros, Tacey X. Viegas, Mei-Chang Kuo, Hema Gursahani, Chester Leach, Yuan Song
-
Patent number: 11129794Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchioalveolar lavage followed by assaying residual lung material.Type: GrantFiled: June 27, 2018Date of Patent: September 28, 2021Assignee: Nektar TherapeuticsInventors: C. Simone Jude-Fishburn, David Lechuga-Ballesteros, Tacey X. Viegas, Mei-Chang Kuo, Hema Gursahani, Chester Leach, Yuan Song
-
Patent number: 11033631Abstract: The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.Type: GrantFiled: June 9, 2009Date of Patent: June 15, 2021Assignee: Nektar TherapeuticsInventors: Michael A. Eldon, C. Simone Jude-Fishburn, Hema Gursahani, Myong Gyong Lee
-
Patent number: 10806794Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.Type: GrantFiled: August 21, 2018Date of Patent: October 20, 2020Assignee: Nektar TherapeuticsInventors: C. Simone Jude-Fishburn, Laurie A. VanderVeen, Timothy A. Riley
-
Publication number: 20190070251Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.Type: ApplicationFiled: April 28, 2017Publication date: March 7, 2019Inventors: Mary J. Bossard, Steven O. Roczniak, Harold Zappe, Yujun Wang, Ping Zhang, Dawei Sheng, C. Simone Jude-Fishburn, Elizabeth Louise Minamitani, Xiaofeng Liu, Haim Moskowitz, Dennis G. Fry, Cherie F. Ali, Christine Taylor Brew
-
Publication number: 20180353609Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.Type: ApplicationFiled: August 21, 2018Publication date: December 13, 2018Inventors: C. Simone Jude-Fishburn, Laurie A. VanderVeen, Timothy A. Riley
-
Patent number: 10092656Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.Type: GrantFiled: August 4, 2016Date of Patent: October 9, 2018Assignee: Nektar TherapeuticsInventors: C. Simone Jude-Fishburn, Laurie A. VanderVeen, Timothy A. Riley
-
Patent number: 9682153Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.Type: GrantFiled: March 20, 2015Date of Patent: June 20, 2017Assignee: Nektar TherapeuticsInventors: Mary J. Bossard, Steven O. Roczniak, Harold Zappe, Yujun Wang, Ping Zhang, Dawei Sheng, C. Simone Jude-Fishburn, Elizabeth Louise Minamitani, Xiaofeng Liu, Haim Moskowitz, Dennis G. Fry, Cherie F. Ali, Christine Taylor Brew
-
Publication number: 20170028077Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.Type: ApplicationFiled: August 4, 2016Publication date: February 2, 2017Inventors: C. Simone Jude-Fishburn, Laurie A. VanderVeen, Timothy A. Riley
-
Publication number: 20160243111Abstract: The invention provides opioid agonists covalently bound to a water-soluble oligomer having reduced potential for substance abuse and uses thereof. The compounds of the invention possess altered pharmacokinetic profiles relative to the opioid agonists alone, but are not subject to the risk of physical tampering that allows for the recovery and abuse of the opioid agonist associated with certain alternative delivery formulations.Type: ApplicationFiled: February 18, 2016Publication date: August 25, 2016Inventors: C. Simone Jude-Fishburn, Timothy A. Riley, Alberto N. Zacarias, Hema Gursahani
-
Publication number: 20160022828Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.Type: ApplicationFiled: March 20, 2015Publication date: January 28, 2016Inventors: Mary J. Bossard, Steven O. Roczniak, Harold Zappe, Yujun Wang, Ping Zhang, Dawei Sheng, C. Simone Jude-Fishburn, Elizabeth Louise Minamitani, Xiaofeng Liu, Haim Moskowitz, Dennis G. Fry, Cherie F. Ali, Christine Taylor Brew
-
Patent number: 9155797Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.Type: GrantFiled: July 22, 2014Date of Patent: October 13, 2015Assignee: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
-
Publication number: 20140329895Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.Type: ApplicationFiled: July 22, 2014Publication date: November 6, 2014Inventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
-
Patent number: 8829043Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.Type: GrantFiled: February 6, 2009Date of Patent: September 9, 2014Assignee: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
-
Publication number: 20130023553Abstract: Provided are methods for reducing the addiction potential and/or reducing one or more CNS-side effects related to the administration of an opioid analgesic drug by administering the opioid analgesic drug in the form of an oligomeric polyethylene glycol conjugate compound. The compounds provided demonstrate notably reduced potential for substance abuse, and possess altered pharmacokinetic profiles relative to the opioid agonists alone, but are not subject to the risk of physical tampering that allows for the recovery and abuse of the opioid agonist associated with certain alternative delivery formulations.Type: ApplicationFiled: January 12, 2011Publication date: January 24, 2013Applicant: Nektar TherapeuticsInventors: C. Simone Jude-Fishburn, Timothy A. Riley, Alberto N. Zacarias, Hema Gursahani
-
Publication number: 20120022063Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.Type: ApplicationFiled: February 6, 2009Publication date: January 26, 2012Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
-
Publication number: 20110237614Abstract: The invention provides opioid agonists covalently bound to a water-soluble oligomer having reduced potential for substance abuse and uses thereof. The compounds of the invention possess altered pharmacokinetic profiles relative to the opioid agonists alone, but are not subject to the risk of physical tampering that allows for the recovery and abuse of the opioid agonist associated with certain alternative delivery formulations.Type: ApplicationFiled: September 16, 2009Publication date: September 29, 2011Applicant: Nektar TherapeuticsInventors: C. Simone Jude-Fishburn, Timothy A. Riley, Alberto N. Zacarias, Hema Gursahani
-
Publication number: 20110195940Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature. Exemplary potent HIV protease inhibitors are mono-m-PEG3-atazanavir, mPEGn-N-darunavir (wherein n is 3 or 5), mPEGn-NHCO-saquinavir (wherein n is 5 or 7), and di-mPEG3-atazanavir.Type: ApplicationFiled: September 17, 2009Publication date: August 11, 2011Applicant: Nektar TherapeuticsInventors: C. Simone Jude-Fishburn, Laurie A. Vander Veen, Timothy A. Riley
-
Publication number: 20110171163Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: July 14, 2011Applicant: Nektar TherapeuticsInventors: Dawei Sheng, Harold Zappe, C. Simone Jude-Fishburn, Steven O. Roczniak, Mary J. Bossard